BLA 103949 · Schering
Pegintron
Peginterferon Alfa-2b
NovelOrphanLast checked: Nov 20, 2026Latest source record: Jan 8, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Jan 19, 2001
Approved uses
8
Original approval plus efficacy supplements
Registered trials
285
93 Phase 3, 9 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 18, 2013 Supplement 5259 · Efficacy ReviewLabelLetter
- Mar 29, 2011 Supplement 5153 · Efficacy · priority review OrphanLabelLetter
- May 8, 2009 Supplement 5172 · Efficacy LabelLetter
- Mar 10, 2009 Supplement 5125 · Efficacy LabelLetter
- Dec 11, 2008 Supplement 5171 · Efficacy · priority review Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewLabel
- Mar 26, 2008 Supplement 5123 · Efficacy
- Aug 7, 2001 Supplement 5002 · Efficacy · priority review LabelLetterReview
- Jan 19, 2001 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
11 products under this application
- PEGINTRON · PEGINTERFERON ALFA-2B 120UG/0.5ML · SYRINGE, · Prescription
- PEGINTRON · PEGINTERFERON ALFA-2B 80UG/0.5ML · SYRINGE, · Prescription
- PEGINTRON · PEGINTERFERON ALFA-2B 150UG/0.5ML · VIAL, · Prescription
- SYLATRON · PEGINTERFERON ALFA-2B 444 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL · VIAL, · Prescription
- PEGINTRON · PEGINTERFERON ALFA-2B 80UG/0.5ML · VIAL, · Prescription
- SYLATRON · PEGINTERFERON ALFA-2B 296 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL · VIAL, · Prescription
- PEGINTRON · PEGINTERFERON ALFA-2B 150UG/0.5ML · SYRINGE, · Prescription
- PEGINTRON · PEGINTERFERON ALFA-2B 50UG/0.5ML · SYRINGE, · Prescription
- SYLATRON · PEGINTERFERON ALFA-2B 888 MCG LYOPHILIZED POWDER PER SINGLE-USE VIAL · VIAL, · Prescription
- PEGINTRON · PEGINTERFERON ALFA-2B 120UG/0.5ML · VIAL, · Prescription
- PEGINTRON · PEGINTERFERON ALFA-2B 50UG/0.5ML · VIAL, · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Peginterferon Alfa-2b" as an intervention, any sponsor and status, largest first.
Third Affiliated Hospital, Sun Yat-Sen UniversityAcademic, hospital or other
NCT05182463 · 5,000 participants (planned) · Start Jan 8, 2022 · Primary completion Dec 13, 2026
Drug: Peginterferon Alfa-2B; Nucleoside Analogs · For: Hepatitis B, Chronic
Sites: Guangzhou, China
- Comparison of PEG-Intron and Two Different Doses of Ribavirin for the Treatment of Chronic Hepatitis C In Treatment Naïve SubjectsPivotal-lookingCompleted
Weill Medical College of Cornell UniversityAcademic, hospital or other
NCT00299936 · 5,000 participants
Drug: Ribavirin, PEG-Intron · For: Chronic Hepatitis C
- Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00081770 · 4,469 participants · Start Mar 2004 · Primary completion Nov 2007
Drug: PegIntron (peginterferon alfa-2b; SCH 54031); PegIntron (peginterferon alfa-2b; SCH 54031) and 3 more · For: Hepatitis C, Chronic
- PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00039871 · 2,333 participants · Start May 2002 · Primary completion Sep 2007
Drug: PegIntron (peginterferon alfa-2b; SCH 54031); REBETOL (ribavirin; SCH 18908) · For: Hepatitis; Hepatitis C, Chronic; Fibrosis and 1 more
- Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00689390 · 1,954 participants · Start Feb 20, 2007 · Primary completion Oct 13, 2014
Drug: Boceprevir; Narlaprevir and 2 more · For: Hepatitis C, Chronic; Hepacivirus
Fang WangAcademic, hospital or other
NCT05792761 · 1,900 participants (planned) · Start May 6, 2021 · Primary completion Dec 31, 2025
Drug: Peginterferon alfa-2b combined and ETV · For: Chronic HBV Infection
Sites: Shenzhen, China
- Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00705432 · 1,472 participants · Start Aug 2008 · Primary completion May 2010
Drug: Peginterferon alfa-2b (PEG); Ribavirin (RBV) and 2 more · For: Hepatitis C, Chronic
- Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00265395 · 1,428 participants · Start Dec 2004 · Primary completion May 2008
Drug: Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®); Combination of pegylated interferon alfa-2b and ribavirin · For: Hepatitis C, Chronic
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Boceprevir for previously treated chronic HCV genotype 1 infection.
Bacon BR, Gordon SC, Lawitz E, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Comparative Study
- Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.
Singal AK, Jampana SC, Anand BS · Dig Dis Sci 2011 · Meta-Analysis, Systematic Review
- Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.
Hayashi N, Okanoue T, Tsubouchi H, et al. · J Viral Hepat 2012 · Clinical Trial, Phase III
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C.
Krawitt EL, Ashikaga T, Gordon SR, et al. · J Hepatol 2005 · Clinical Trial, Comparative Study
- Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.
Buti M, Lurie Y, Zakharova NG, et al. · Hepatology 2010 · Multicenter Study, Randomized Controlled Trial
Sponsor: Merck & Co. · Also marketed as Sylatron
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.